Bioanalysis of Biologics and Biosimilars

In biological substances coming from preclinical and clinical studies, we have a long track record of developing and validating bioanalytical methods from scratch or working with transferred methods. Furthermore, we have a great capacity for processing samples. In order to quantify the plasma or serum levels of biologics for PK calculations, we mostly work with immunology methods such as ELISA, ECLA or RIA, but we also have experience in mass spectrometry of large molecules.

We are fully compliance with the EMA guideline on Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins and other regulations and guidelines of the FDA. Our experience covers a wide range of different kind of large molecules:

  • Hormones
  • Biosimilars: proteins and monoclonal antibodiesresizedimage300198-SECTORImager2400A.png
  • Innovative proteins and monoclonal antibodies
  • Antibodies drug conjugates
  • Therapeutic peptides: innovative, generic and hybrid formulations
  • Polysaccharides

Our immunology platform have different technologies available to cover the whole range of needs:

  • ECLA: electrochemiluminiscence using MesoScale Discovery instrument
  • ELISA: direct, sandwich, bridge, competitive using different detection techniques (colorimetric, fluorescence, time resolved fluorescence, luminiscence).
  • RIA: radioimmunoassay testing using I125 

Our mass spec platform counts with 8 LC-MS instruments with different ranges of sensitivity. The strategy to quantify large molecules by mass spec consists on a tryptic digestion of the protein followed by the measurement of the main peptides.


        ► Download Catalog


Contact form

Files must be less than 2 MB.
Allowed file types: pdf doc docx odt.